OTCMKTS:MAYNF - HedgePath Pharmaceuticals Stock Price, News & Analysis

-0.01 (-2.80 %)
(As of 09/19/2019 03:00 PM ET)
Today's Range
Now: $0.3470
50-Day Range
MA: $0.33
52-Week Range
Now: $0.3470
Volume10,000 shs
Average Volume31,614 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products worldwide. It operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The company also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited is based in Salisbury South, Australia.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Phone61 8 8209 2666



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive MAYNF News and Ratings via Email

Sign-up to receive the latest news and ratings for MAYNF and its competitors with MarketBeat's FREE daily newsletter.

HedgePath Pharmaceuticals (OTCMKTS:MAYNF) Frequently Asked Questions

What is HedgePath Pharmaceuticals' stock symbol?

HedgePath Pharmaceuticals trades on the OTCMKTS under the ticker symbol "MAYNF."

What is the consensus analysts' recommendation for HedgePath Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HedgePath Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for HedgePath Pharmaceuticals.

Has HedgePath Pharmaceuticals been receiving favorable news coverage?

News coverage about MAYNF stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. HedgePath Pharmaceuticals earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for HedgePath Pharmaceuticals.

Who are some of HedgePath Pharmaceuticals' key competitors?

Some companies that are related to HedgePath Pharmaceuticals include Bayer (BAYN), OTSUKA HOLDINGS/ADR (OTSKY), Roche (SNYNF), Sanofi (SAN) and SINR PHAR/PAR VTG FPD 0.01 (SPH).

Who are HedgePath Pharmaceuticals' key executives?

HedgePath Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott Anthony Richards, MD, CEO & Exec. Director (Age 55)
  • Mr. Nick Freeman BCom, CA, Group CFO & Company Sec.
  • Mr. Stefan J. Cross, Pres of International Operations (Age 46)
  • Dr. Ilana Stancovski, Chief Scientific Officer & Head of European Market Devel.
  • Ms. Lisa Pendlebury, VP of Investor Relations & Communications

How do I buy shares of HedgePath Pharmaceuticals?

Shares of MAYNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is HedgePath Pharmaceuticals' stock price today?

One share of MAYNF stock can currently be purchased for approximately $0.3470.

What is HedgePath Pharmaceuticals' official website?

The official website for HedgePath Pharmaceuticals is http://www.maynepharma.com/.

How can I contact HedgePath Pharmaceuticals?

The company can be reached via phone at 61 8 8209 2666.

MarketBeat Community Rating for HedgePath Pharmaceuticals (OTCMKTS MAYNF)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  14
MarketBeat's community ratings are surveys of what our community members think about HedgePath Pharmaceuticals and other stocks. Vote "Outperform" if you believe MAYNF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MAYNF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel